The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey


Uzunkopru C., Tutuncu M. , Gunduz T. , GÜMÜŞ H., Sen S., Demir S., ...Daha Fazla

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası:
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1111/ijcp.14158
  • Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Özet

Background Neuromyelitis optica spectrum disorders (NMOSD) are a group of antibody-mediated chronic inflammatory diseases of the central nervous system. Rituximab is a monoclonal antibody that leads to a reduction in disease activity.